1. Home
  2. MAIA vs NTRB Comparison

MAIA vs NTRB Comparison

Compare MAIA & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • NTRB
  • Stock Information
  • Founded
  • MAIA 2018
  • NTRB 2016
  • Country
  • MAIA United States
  • NTRB United States
  • Employees
  • MAIA N/A
  • NTRB N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • NTRB Industrial Specialties
  • Sector
  • MAIA Health Care
  • NTRB Health Care
  • Exchange
  • MAIA Nasdaq
  • NTRB Nasdaq
  • Market Cap
  • MAIA 62.4M
  • NTRB 77.9M
  • IPO Year
  • MAIA 2022
  • NTRB N/A
  • Fundamental
  • Price
  • MAIA $2.82
  • NTRB $6.17
  • Analyst Decision
  • MAIA
  • NTRB
  • Analyst Count
  • MAIA 0
  • NTRB 0
  • Target Price
  • MAIA N/A
  • NTRB N/A
  • AVG Volume (30 Days)
  • MAIA 60.0K
  • NTRB 28.2K
  • Earning Date
  • MAIA 11-05-2024
  • NTRB 12-11-2024
  • Dividend Yield
  • MAIA N/A
  • NTRB N/A
  • EPS Growth
  • MAIA N/A
  • NTRB N/A
  • EPS
  • MAIA N/A
  • NTRB N/A
  • Revenue
  • MAIA N/A
  • NTRB $1,803,816.00
  • Revenue This Year
  • MAIA N/A
  • NTRB N/A
  • Revenue Next Year
  • MAIA N/A
  • NTRB N/A
  • P/E Ratio
  • MAIA N/A
  • NTRB N/A
  • Revenue Growth
  • MAIA N/A
  • NTRB N/A
  • 52 Week Low
  • MAIA $0.82
  • NTRB $1.93
  • 52 Week High
  • MAIA $5.99
  • NTRB $9.60
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 50.98
  • NTRB 50.57
  • Support Level
  • MAIA $2.36
  • NTRB $5.24
  • Resistance Level
  • MAIA $2.72
  • NTRB $6.40
  • Average True Range (ATR)
  • MAIA 0.22
  • NTRB 0.71
  • MACD
  • MAIA 0.02
  • NTRB -0.12
  • Stochastic Oscillator
  • MAIA 72.28
  • NTRB 33.23

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.

About NTRB Nutriband Inc.

Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

Share on Social Networks: